BRIDGEWATER, N.J. A new drug for treating heart problems has become available in the United States.
Sanofi-Aventis announced this week the availability of Multaq (dronedarone) tablets in the 400 mg strength. The drug is used to treat atrial fibrillation and atrial flutter. The Food and Drug Administration approved the drug on July 1.
“Multaq may help patients with atrial fibrillation or atrial flutter stay out of the hospital, which is an important factor in treatment that is often not addressed,” Pennsylvania State University College of Medicine cardiologist Gerald Naccarelli said in a statement. “We welcome a new option that may help patients with Afib or Aflutter manage their disease.”